Antibody Drug Conjugate Manufacturing: Market Size & Forecast 2026

The global Antibody Drug Conjugate (ADC) manufacturing market sits at approximately USD 23.5 billion in 2025 (base year), expanding to USD 77.1 billion by 2032 at an 18.5% CAGR [Claight estimate: consensus range 15-22% CAGR, mid-2026 base year extrapolation]. This structurally tight market balances against a concentrated supply base dominated by roughly 35 CDMOs that collectively hold the majority of commercial-scale capacity. The dominant cost driver is the cytotoxic payload component at 25-30% of finished ADC cost, while capital expenditure for high-containment manufacturing suites, typically USD 10 million to USD 500 million per facility, sets a high structural barrier to new capacity additions. > **Analyst Take.** The call is to qualify dual-region CDMO capacity now, before pipeline demand tightens the supply base further. We read the 18.5% consensus CAGR as achievable but only if th

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.